Farris Maria, Goodall Stephen, De Abreu Lourenco Richard, Mulhern Brendan, Manipis Kathleen, Meshcheriakova Elena, Lewandowska Milena
Novartis Pharmaceuticals Australia, Macquarie Park, Australia.
Centre for Health Economic Research and Evaluation, University of Technology Sydney, Sydney, Australia.
Pharmacoecon Open. 2024 Nov;8(6):911-922. doi: 10.1007/s41669-024-00515-5. Epub 2024 Aug 5.
Inherited retinal disease (IRD) causes progressive loss of visual function, degenerating towards complete blindness. Economic evaluation of gene therapies for rare forms of genetic IRDs have had to rely on health-related quality of life (HR-QoL) estimates from other diseases because there is limited data available for such a rare condition. This study aimed to estimate Australian societal-based utility values for IRD health states that can be used in cost-utility analyses (CUA) using a time trade-off (TTO) protocol adapted from a UK study.
The EuroQol Valuation Technology (EQVT) protocol composite TTO (cTTO) framework was followed, which includes worse-than-death (WTD) states and quality control (QC) measures. Preferences were collected from a general population sample of 110 Australian adult participants. Five health state vignettes from the UK study which had been validated with patients and clinicians were presented randomly to participants during videoconferencing (VC) interviews with one of four interviewers. Technical and protocol feasibility were assessed in a pilot of 10 interviews. QC measures were used to monitor interviewers' performance during the study.
One participant withdrew consent. The final analysis was conducted on 109 respondents (including 4 non-traders). The average time to complete the interview was 44.2 minutes (SD 8.7). Participants reported mean visual analogue scale (VAS) scores between 63.15 for 'moderate impairment' and 17.98 for 'hand motion' to 'no light perception'. Mean health state utilities (HSU) varied between 0.76 (SD 0.26) in 'moderate impairment', and 0.20 (SD 0.58) in 'hand motion' to 'no light perception'. Of all HSU evaluations, 14% were considered WTD which most commonly occurred in the most severe visually impaired health state.
This study provides valuable information on HSUs across a range of IRD health states from the Australian general population perspective. The utilities obtained in this study can be used as inputs into CUA of IRD therapies.
遗传性视网膜疾病(IRD)会导致视觉功能逐渐丧失,最终发展为完全失明。由于针对罕见形式的遗传性IRD的基因疗法的经济评估缺乏此类罕见病症的可用数据,因此不得不依赖于其他疾病的健康相关生活质量(HR-QoL)估计值。本研究旨在通过采用源自英国一项研究的时间权衡(TTO)方案,估计澳大利亚社会层面针对IRD健康状态的效用值,这些效用值可用于成本效用分析(CUA)。
遵循欧洲生活质量评估技术(EQVT)方案的综合TTO(cTTO)框架,其中包括比死亡更糟(WTD)状态和质量控制(QC)措施。从110名澳大利亚成年参与者的普通人群样本中收集偏好。在与四名面试官之一进行的视频会议(VC)访谈中,将英国研究中的五个已通过患者和临床医生验证的健康状态 vignette 随机呈现给参与者。在10次访谈的试点中评估了技术和方案的可行性。在研究期间,使用QC措施来监测面试官的表现。
一名参与者撤回了同意。对109名受访者(包括4名非交易者)进行了最终分析。完成访谈的平均时间为44.2分钟(标准差8.7)。参与者报告的平均视觉模拟量表(VAS)分数在“中度损害”的63.15和“手动”至“无光感”的17.98之间。平均健康状态效用(HSU)在“中度损害”中的范围为0.76(标准差0.26),在“手动”至“无光感”中的范围为0.20(标准差0.58)。在所有HSU评估中,14%被认为是WTD,最常见于最严重的视力受损健康状态。
本研究从澳大利亚普通人群的角度提供了关于一系列IRD健康状态的HSU的宝贵信息。本研究中获得的效用值可作为IRD疗法CUA的输入。